Neuropozyne (Nu-poz) is a drug manufactured by VersaLife. It helps prevent Darrow Deficiency Syndrome, a condition caused due to build-up of scar tissue that can block electrical signals between augmentation electrodes and human tissue that can ultimately lead to rejection. Unlike non-cybernetic implants, which can be made from hypoallergenic materials, there is a requirement for any cybernetic augmentation that will "feel" and can be moved by the mind to have a neuroprosthetic junction. In essence, this is a biochip located within the brain to act as the interface between body and machine.
The main problem with implanting the biochip is that it causes tissue to build up around the junction, causing "nerve scars" that disrupt the integrity of the neuroprosthetic junction causing rejection syndrome, also known as Darrow Deficiency Syndrome (DDS).
Neuropozyne is available by prescription only and weekly doses are required to prevent the disruption of the junction. Although it is not produced with especially rare materials, its distribution is heavily monitored.